BUZZ-Supernus Pharma sinks after depression drug fails mid-stage trial goal

Shares of drugmaker Supernus Pharmaceuticals SUPN.O fall ~22% to $31 premarket

On late Tuesday, co said its depression drug, SPN-820, did not meet main goal of reduction in depressive symptoms in a mid-stage trial

Trial tested 250 patients with treatment-resistant depression and found no statistically significant change compared to a placebo

Trial used Montgomery-Asberg Depression Rating Scale to measure severity of depression symptoms such as sadness, inner tension, sleep reduction and inability to feel

SUPN gained 30.4% in 2024